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ABSTRACT 
Eight new diterpenoids, kaempulchraols A−H (1−8), along with five known analogues were 
isolated from the CHCl3 soluble extract of rhizomes of Kaempferia pulchra of Myanmar. The 
structures of these compounds were elucidated using extensive spectroscopic techniques 
including X-ray diffraction analysis. All the isolates were tested for their antiproliferative 
activity against a panel of five human cancer cell lines (A549, human lung cancer; HeLa, 
human cervix cancer; PANC-1 and PSN-1, human pancreatic cancer, MDA-MB-231, human 
breast cancer) and TIG-3, normal human primary fibroblast cells. Kaempulchraol F (6) 
exhibited weak activity against human pancreatic PSN-1 cell line with an IC50 value of 12.3 
µM.  
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Cancer is a leading cause of death worldwide.1 In anticancer drug discovery, natural 
products characterized from medicinal plants play an important role. Vincristine, irinotecan, 
etoposide, and paclitaxel are examples of plant-derived compounds that are being employed 
in cancer treatment.2 According to GLOBOCAN 2012 report, the five most frequent cancers 
in Myanmar are lung, breast, cervix uteri, stomach, and liver.1 Many of Myanmar medicinal 
plants have been used to prevent, alleviate, and cure human disease by the Myanmar people 
since time immemorial. In our ongoing research for the discovery of anticancer agents from 
Myanmar medicinal plants,3−6 we screened the crude extracts against a panel of five human 
cancer cell lines (A549, human lung cancer; HeLa, human cervix cancer; PANC-1 and PSN-1, 
human pancreatic cancer, MDA-MB-231, human  breast  cancer) and TIG-3, normal 
human primary fibroblast cells. The CHCl3 soluble fraction of rhizomes of Kaempferia 
pulchra exhibited reasonable antiproliferative activity against the tested cancer cell lines. 
Kaempferia pulchra Ridl., a perennial herb of the Zingiberaceae family is cultivated in some 
tropical countries including Myanmar, Indonesia, Malaysia, and Thailand. It is commonly 
known as “Shan-pan-oot” in Myanmar, and has been extensively used for cough, blood 
stimulation, carminative, quenching heat, deodorant, urinary tract infection, diuretic, and 
mellitus diabetes.7 It has been reported to possess anti-inflammatory8 and antitumor 
activities.9 The rhizomes have been used locally for the self-medication by cancer and AIDS 
patients in Myanmar. Previous studies reported the presence of sandaracopimaradiene 
diterpenoids and ethyl 4-methoxy-trans-cinnamate.8, 10 Herein, the isolation, structural 
elucidation, and antiproliferative activity of the isolated compounds are reported. 
 
RESULTS AND DISCUSSION 
The chloroform extract of K. pulchra exhibited reasonable antiproliferative activity against a 
panel of five human cancer cell lines (A549, human lung cancer; HeLa, human cervix cancer; 
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PANC-1 and PSN-1, human pancreatic cancer, MDA-MB-231, human breast cancer). Thus, 
it was subjected to a series of chromatographic separations which furnished eight new 
isopimarane diterpenoids, named kaempulchraols A−H (1−8) together with five known ones 
[9α-hydroxyisopimara-8(14),15-dien-7-one (9),11 7β, 9α-dihydroxypimara-8(14),15-diene 
(10),12 1α, 11α-dihydroxypimara-8(14),15-diene (11),13 1α, 2α-dihydroxypimara- 
8(14),15-diene (12),8 and (2R)-ent-2hydroxyisopimara-8(14),15-diene (13)]. 14   
Compound 1 was obtained as colorless needles, and its molecular formula was determined 
as C21H34O2 via 13C NMR and HREIMS data. The IR spectrum of 1 showed absorption bands 
of hydroxy and olefinic groups at 3519 and 1634 cm-1, respectively. The 1H NMR spectrum 
(Table 1) displayed signals due to terminal vinyl protons [δH 6.07, dd, (J = 16.5, 12.0 Hz, 
H-15), 5.07, dd (J = 16.5, 1.5 Hz, H-16a), 5.05, dd (J = 12.0, 1.5 Hz, H-16b)], three methines 
including two oxygenated ones [δH 4.54, t (J = 5.0 Hz, H-6), 3.13, s (H-14), 1.27, br s (H-5)], 
six methylene groups, one methoxy group [δH 3.46, s (OMe-14)], and four tertiary methyls 
[δH 1.03 (H3-17), 1.23 (H3-18), 0.98 (H3-19), 1.38 (H3-20)]. The 13C NMR spectrum (Table 
3) revealed 21 signals including four olefinic carbons (δC 144.4, 140.7, 123.7, 112.4), two 
oxygenated methines (δC 88.9, 66.1), one methine (δC 53.6), three quaternary carbons (δC 
40.17, 37.8, 34.3), six methylenes (δC 43.3, 40.7, 40.18, 31.4, 20.4, 19.4), one methoxy (δC 
62.1), and four methyls (δC 33.7, 24.3, 22.9, 21.9). These data suggested 1 to be an 
isopimarane diterpenoid similar to those reported by Tuchinda et al.8 However, significant 
differences included the absence of the trisubstituted Δ8(14) double bond of the 
sandaracopimaradiene skeleton and the presence of a tetrasubstituted Δ8(9) double bond in 1, 
which was confirmed from the 1H−13C HMBC correlations of H3-20 (δH 1.38, s) and H2-12 
(δH 1.39, 1.69, both m) to C-9 (δC 140.7) and those of H2-7 to C-8 (δC 123.7) and C-9 
(Supporting Information Figure S2). Thus, the skeleton of 1 was considered to be an 
isopimara-8(9),15-diene. The presence of two oxygenated methine protons and one methoxy 
signal suggested the presence of a hydroxy and a methoxy group. The HMBC correlations of 
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H-6 (δH 4.54) to C-5/C-7/C-8/C-10, of H-14 (δH 3.13) to C-8/C-9/C-13/C-15/C-17, and of 
OMe-14 (δH 3.46) to C-14 confirmed the position of hydroxy group at C-6 and that of 
methoxy group at C-14. The relative configuration of 1 was assigned on the basis of a 2D 
NOESY experiment. The NOESY correlations between H-6 and H-5/H3-19 and between 
H-14 and H3-17 suggested the orientation of OH-6 and OMe-14 as β and α, respectively. The 
X-ray crystallographic pattern (Figure 1) confirmed the structure of 1 as 
6β-hydroxy-14α-methoxyisopimara-8(9),15-diene and named kaempulchraol A. 
Compound 2 was obtained as colorless needles having a molecular formula of C21H34O2. 
The 1H and 13C NMR spectroscopic data (Tables 1and 3) of 2 were similar to those of 1. The 
difference was the orientation of methoxy group at C-14 (δH 3.50, s) as β, which was 
confirmed from the 2D NOESY correlations of OMe-14 to H3-17 (δH 1.10, s) and X-ray 
diffraction analysis (Figure 1). Thus, the structure of 2 was assigned as 
6β-hydroxy-14β-methoxyisopimara-8(9),15-diene and named kaempulchraol B. 
Compound 3 was obtained as colorless needles and its molecular formula was shown to be 
C20H32O2 by HREIMS and 13C NMR data. The 1H and 13C NMR spectroscopic data of 3 
(Tables 1and 3) were also similar to those of 1 except for the absence of the C-14 methoxy 
group (δH 3.46, δC 62.1) in 3. Instead of the methoxy group, the presence of a hydroxy group 
in 3 was in agreement with its HMBC correlations between the oxygenated methine (δH 3.61, 
d, J = 6.1 Hz, H-14) and C-7/C-9/C-15/C-17 (Supporting Information Figure S2). On the 
basis of X-ray diffraction analysis data (Figure 1), the relative configuration of 3 was similar 
to that of 1. Accordingly, 3 was identified as 6β, 14α-dihydroxyisopimara-8(9),15-diene and 
named kaempulchraol C. 
Compound 4 was isolated as colorless needles. The HREIMS of 4 exhibited an [M]+ ion at 
m/z 304.2407 corresponding to the molecular formula C20H32O2. Its 1H and 13C NMR 
spectroscopic data (Tables 1 and 3) as well as HMBC correlations were similar to those of 3 
and thus 4 was assumed to be an isomer of 3. The significant differences were the splitting 
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patterns of H-14 [3: 3.61, d (J = 6.1 Hz); 4: δH 3.37, br s] and X-ray diffraction patterns 
(Figure 1). Thus, the orientation of C-14 hydroxy group in 4 was concluded to be opposite to 
that of 3. Hence, the structure of 4 was elucidated as 6β, 
14β-dihydroxyisopimara-8(9),15-diene and named kaempulchraol D. 
Compound 5 was obtained as colorless plates. The molecular formula, C20H32O2 was 
determined by HREIMS and 13C NMR data. The IR spectrum revealed absorption bands at 
3388, 2939, and 1634 cm-1 ascribable to be the presence of hydroxy and olefinic groups. The 
1H NMR spectrum (Table 2) of 5 displayed signals for a sandaracopimaradiene type skeleton 
including terminal vinylic protons [δH 5.77, dd (J = 17.7, 10.3 Hz, H-15), 4.92, dd (J = 17.7, 
1.5 Hz, H-16a), 4.90, dd (J = 10.3, 1.5 Hz, H-16b)], an olefinic methine [δH 5.43, br t (J = 1.7 
Hz, H-14)] and four methyl singlets [δH 1.09 (H3-17, H3-20), 1.26 (H3-18), 1.03 (H3-19)]. 
Analyses of the HMQC and 13C NMR spectroscopic data (Table 3) of 5 indicated the 
presence of four olefinic carbons, four methines including two oxygenated ones, three 
quaternary carbons, five methylenes, and four methyls. These data revealed 5 to possess a 
dihydroxysandaracopimaradiene skeleton. The HMBC correlations (Supporting Information 
Figure S2) between H-1 (δH 3.64, br s) and C-3/C-5/C-9/C-20 and between H-6 (δH 4.36, d, J 
= 2.3 Hz) and C-4/C-8/C-10 showed the attachment of these hydroxy groups at C-1 and C-6. 
The 2D NOESY correlations of H-1 and H3-20, of H-6 and H-5/H-9/H3-19 and the X-ray 
diffraction pattern (Figure 1) established the relative configuration of 5 as shown in Chart 1. 
Consequently, its structure was elucidated as 1α, 6β-dihydroxyisopimara-8(14),15-diene and 
named kaempulchraol E.  
Compound 6 was obtained as colorless needles and its molecular formula was shown as 
C20H32O2 by HREIMS and 13C NMR data. The 1H and 13C NMR spectroscopic data (Tables 2 
and 3) of 6 were similar to those of reported sandaracopimaradienes.8 The presence of two 
oxygenated methines at δH 3.75 and δH 3.57 suggested 6 to be a dihydroxy derivative of 
sandaracopimaradiene. The HMBC correlations (Supporting Information Figure S2) between 
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H-1 (δH 3.75, br s) and C-3/C-5/C-9/C-20 and between H-3 (δH 3.57, br s) and 
C-1/C-5/C-18/C-19 confirmed the position of these two hydroxy groups at C-1 and C-3, 
respectively. The orientations of the C-1 and C-3 hydroxy groups were determined by 
NOESY correlations of H-1 and H3-20, and of H-3 and H3-18. Thus, 6 was identified as 1α, 
3α-dihydroxyisopimara-8(14),15-diene and named kaempulchraol F. 
Compound 7 was obtained as an amorphous solid and its molecular formula was observed 
to be C20H30O2 by HREIMS and 13C NMR data. The IR spectrum exhibited absorption bands 
at 3530, 1742, and 1647 cm-1 due to the presence of hydroxy, carbonyl, and olefinic groups, 
respectively. The 1H and 13C NMR spectroscopic data of 7 (Tables 2 and 3) were similar to 
those of 4. The only difference involves the presence of carbonyl carbon (δC 202.1) in 7 
instead of an oxygenated methine (δC 74.8, C-14) of 4. The HMBC correlations of H-15 (δH 
5.80, dd, J = 17.5, 10.7 Hz), H-7α (δH 2.41, m) and H-7β (δH 2.54, m) to this carbonyl carbon 
(Supporting Information Figure S2) supported its C-14 location. The β orientation of the C-6 
hydroxy group was established on the basis of NOESY correlations of H-6 to H-5α and 
H3-19, respectively. Hence, the structure of 7 was concluded to be 
6β-hydroxy-14-oxoisopimara-8(9),15-diene and named kaempulchraol G.  
Compound 8 was isolated as an amorphous solid and its HREIMS (m/z 320.2356) and 13C 
NMR data suggested it to have the molecular formula C20H32O3. Its 1H and 13C NMR data 
(Tables 2 and 3) were similar to those of 6. The only difference involves the presence of an 
additional oxygenated methine (δH 4.33, d, J = 2.5 Hz, δC 69.1) in 8. Thus, 8 was proposed to 
be a trihydroxy derivative of sandaracopimaradiene. On the basis of HMBC correlations of 
H-1 (δH 3.64, br s) to C-3/C-5/C-9/C-20, of H-3 (δH 3.52, br s) to C-1/C-5/C-18/C-19 and of 
H-6 to C-4/C-8/C-10, the locations of the three hydroxy groups were at C-1, C-3, and C-6, 
respectively (Supporting Information Figure S2). The orientations of the C-1, C-3, and C-6 
hydroxy groups were determined by NOESY correlations of H-1 to H3-20 (δH 1.08, s), of H-3 
to H3-18 (δH 1.27, s), and of H-6 to H-5 (δH 1.78, d, J = 1.7 Hz) and H3-19 (δH 1.12, s), 
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respectively. Consequently, the structure of 8 was elucidated as 1α, 3α, 
6β-trihydroxyisopimara-8(14),15-diene and named kaempulchraol H. 
The structure of the known compounds 9−13 (Supporting Information Figure S1) were 
identified by comparison of their observed and reported NMR data. Based on the present 
study, the rhizomes of K. pulchra were found to be a rich source of 6β-hydroxyisopimarane 
diterpenoids. This is the first report for the presence of 8(9),15-isopimarane diterpenoids in 
the rhizomes of K. pulchra which were collected from the middle eastern part of Myanmar.  
All the isolated compounds 1−13 were subjected for antiproliferative activity against five 
human cancer cell lines. Among the tested compounds, only kaempulchraol F (6) exhibited 
weak activity against human pancreatic PSN-1 cell line with an IC50 value of 12.3 µM. 
 
EXPERIMENTAL SECTION 
General Experimental Procedures. The melting points were determined on a Yanaco 
micro melting point apparatus and are uncorrected. Optical rotations were recorded on a 
JASCO P2100 polarimeter. Infrared spectra were recorded as KBr pellets on a Jasco 
FT/IR-460 Plus spectrometer. NMR spectra were recorded at 600 MHz (1H NMR) and 150 
MHz (13C NMR), respectively, on a Varian UNITY 600 spectrometer. Chemical shift values 
were expressed in δ (ppm) downfield from TMS as internal standard. The mass spectra, 
including high-resolution mass spectra, were recorded on a JEOL MStation JMS-700 
spectrometer. Open column chromatography was performed with normal-phase silica gel 
(silica gel 60N, Spherical, neutral, 40−50 µm, Kanto Chemical Co., Inc, Japan) and cosmosil 
75C18-OPN (Nacalai Tesque Inc., Kyoto, Japan). MPLC was done with a Büchi Sepacore 
system (Büchi Labortechnik AG, Flawil, Switzerland). TLC was carried out on precoated 
silica gel 60F254 and RP-18 F254 plates (Merck, 0.25 or 0.50 mm thickness). The cell lines 
such as A549 (human lung cancer), HeLa (human cervix cancer), PANC-1 and PSN-1 
9 
 
(human pancreatic cancer), MDA-MB-231 (human breast cancer), and TIG-3 (normal human 
primary fibroblast cell) were available and maintained in our laboratory. Cell culture flasks 
and 96-well plates were from Corning Inc. (Corning, NY, USA). The SH-1200 Microplate 
Reader® (Corona, Hitachinaka, Japan) was used to measure the absorbance of the cells in the 
antiproliferative activity assay.  
Plant Material. Rhizomes of Kaempferia pulchra Ridl. were collected from Pindaya 
Township, Shan State, Myanmar in September 2013 and identified by the authorized botanist 
of the Department of Botany, University of Yangon. A voucher specimen (TMPW 28301) 
was deposited at the Museum for Materia Medica, Analytical Research Center for 
Ethnomedicines, Institute of Natural Medicine, University of Toyama, Japan.  
Extraction and Isolation. The rhizomes of K. pulchra (500 g) were extracted with CHCl3 
under sonication (1L, 90 min, ×3) at 35 °C and the solvent was evaporated under reduced 
pressure to give 30 g of extract.  
The chloroform extract (30 g) was chromatographed on silica gel with an 
EtOAc−n-hexane solvent system to give seven fractions [1: EtOAc−n-hexane (10:90) eluate, 
0.96 g; 2: EtOAc−n-hexane (15:85) eluate, 1.99 g; 3: EtOAc−n-hexane (20:80) eluate, 6.43 g; 
4: EtOAc−n-hexane (25:75) eluate, 3.52 g; 5: EtOAc−n-hexane (30:70) eluate, 3.84 g; 6: 
EtOAc−n-hexane (40:60) eluate, 1.34 g; 7: EtOAc−n-hexane (50:50) eluate, 3.94 g].  
Fractions 1 and 2 were oily substances. Fraction 3 (6 g) was rechromatographed on 
cosmosil 75C18-OPN with MeCN−acetone−MeOH−H2O (2:2:1:1) to give three subfractions 
[3-1: 0.5 g; 3-2: 4 g; 3-3: 0.5 g]. Subfraction 3-2 (4 g) was separated by MPLC with 
n-hexane−CH2Cl2−EtOAc (100:100:7) [column: polypropylene  (∅ 40 mm × 150 mm); 
flow rate: 20 mL/min] to give kaempulchraols A (1, 40 mg), B (2, 55 mg), C (3, 70 mg), D (4, 
10 mg), and E (5, 473 mg) and 9α-hydroxyisopimara-8(14),15-dien-7-one (9, 15 mg).11 
The 7β, 9α-dihydroxypimara-8(14),15-diene12 (10, 1.2 g) and 1α, 
11α-dihydroxypimara-8(14),15-diene13 (11, 1.1 g) were directly obtained as pure needles 
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from fraction 4.   
Fraction 5 (3.84 g) was rechromatographed on cosmosil 75C18-OPN with 
MeCN−acetone−MeOH−H2O (2:1:1:1) to afford four subfractions [5-1: 2.3 g; 5-2: 0.6 g; 5-3: 
0.5 g; 5-4: 162 mg]. Subfraction 5-1 (2.3 g) was separated by MPLC [column: polypropylene  
(∅ 40 mm × 150 mm); flow rate: 20 mL/min] with n-hexane−CH2Cl2−EtOAc (4.5:4.5:1) 
followed by purification on cosmosil 75C18-OPN with MeOH−H2O (3:1) to give 1α, 
2α-dihydroxypimara-8(14),15-diene8 (12, 354 mg), kaempulchraol F (6, 700 mg), and 
mixture (349 mg). That mixture (349 mg) was subjected to normal-phase preparative TLC 
with n-hexane− CH2Cl2−acetone (4:4:1) to give kaempulchraols C (3, 50.5 mg) and G (7, 
15.2 mg), and 11 (144 mg) and (2R)-ent-2hydroxyisopimara-8(14),15-diene14 (13, 10 mg).  
Fraction 6 (1.34 g) was rechromatographed on cosmosil 75C18-OPN with 
MeCN−acetone−MeOH−H2O (2:1:1:1) to afford three subfractions [6-1: 1.15 g; 6-2: 74 mg; 
6-3: 63 mg]. Further purification of subfraction 6-1 (1.15 g) by MPLC [column: 
polypropylene (∅ 40 mm × 150 mm); flow rate: 20 mL/min] with CHCl3:EtOAc (95:5) 
afforded kaempulchraols  D (4, 56 mg) and H (8, 892 mg). 
Kaempulchraol A (1): colorless needles (n-hexane:CH2Cl2, 9:1); mp 130−133 °C; [α]25D 
−43 (c 0.1, MeOH); IR (KBr) νmax 3519, 2937, 2363, 1829, 1662, 1634, 1460, 1219, 1155 
cm-1; 1H and 13C NMR data, see Tables 1 and 3; EIMS m/z 318 [M]+ (17); HREIMS m/z 
318.2559 [M]+ (calcd for C21H34O2 318.2559).  
Kaempulchraol B (2): colorless needles (n-hexane:CH2Cl2, 9:1); mp 95−98 °C; [α]25D 
+121 (c 0.1, MeOH); IR (KBr) νmax 3427, 2918, 1637, 1459, 1224, 1090, 1003, 940, 917 
cm-1; 1H and 13C NMR data, see Tables 1 and 3; EIMS m/z 318 [M]+ (18); HREIMS m/z 
318.2567 [M]+ (calcd for C21H34O2 318.2559).  
Kaempulchraol C (3): colorless needles (acetone); mp 110−113 °C; [α]25D −16 (c 0.1, 
MeOH); IR (KBr) νmax 3339, 2920, 1655,1640, 1458, 1288, 1259, 1089, 1009, 984 cm-1; 1H 
and 13C NMR data, see Tables 1 and 3; EIMS m/z 304 [M]+ (6); HREIMS m/z 304.2396 [M]+ 
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(calcd for C20H32O2 304.2402).  
Kaempulchraol D (4): colorless needles (acetone); mp 120−123 °C; [α]25D +93 (c 0.05, 
MeOH); IR (KBr) νmax 3465, 3360, 2916, 1634, 1457, 1213, 1089, 970 cm-1; 1H and 13C 
NMR data, see Tables 1 and 3; EIMS m/z 304 [M]+ (6); HREIMS m/z 304.2407 [M]+ (calcd 
for C20H32O2 304.2402).  
Kaempulchraol E (5): colorless plates (n-hexane:CH2Cl2, 9:1); mp 145−150 °C; [α]25D 
+51 (c 0.1, MeOH); IR (KBr) νmax 3388, 2939, 1634, 1449, 1224, 1194, 979, 947, 912 cm-1; 
1H and 13C NMR data, see Tables 1 and 3; EIMS m/z 304 [M]+ (18); HREIMS m/z 304.2425 
[M]+ (calcd for C20H32O2 304.2402).  
Kaempulchraol F (6): colorless needles (CH2Cl2); mp 165−170 °C; [α]25D −19 (c 0.1, 
MeOH); IR (KBr) νmax 3293, 2946, 1636, 1457, 1064, 998 cm-1; 1H and 13C NMR data, see 
Tables 1 and 3; EIMS m/z 304 [M]+ (15); HREIMS m/z 304.2395 [M]+ (calcd for C20H32O2 
304.2402). 
Kaempulchraol G (7): amorphous solid; [α]25D +93 (c 0.1, MeOH); IR (KBr) νmax 3530, 
2924, 1742, 1647, 1618, 1457, 1221, 1060, 1018, 923 cm-1; 1H and 13C NMR data, see Tables 
2 and 3; EIMS m/z 302 [M]+ (28); HREIMS m/z 302.2240 [M]+ (calcd for C20H30O2 
302.2246).  
Kaempulchraol H (8): amorphous solid; [α]25D −55 (c 0.1, MeOH); IR (KBr) νmax 3568, 
3278, 2952, 1635, 1450, 1193, 1066, 981 cm-1; 1H and 13C NMR data, see Tables 2 and 3; 
EIMS m/z 320 [M]+ (8); HREIMS m/z 320.2356 [M]+ (calcd for C20H32O3 320.2351).  
X-ray Crystallographic Analysis of Kaempulchraols A−E (1−5). X-ray data for 
compounds 1−5 were collected on a Bruker APEX 2 CCD area detector diffractometer with a 
multi-layered confocal mirror Helios (ϕ−ω scans), Mo Kα radiation (λ = 0.71069 Å) and the 
radiation source is Bruker TXS fine-focus rotating anode. Bruker APEX 2 was used for cell 
refinement and data reduction. The programs SHELXL-97, SHELXL-2014, and PLATON 
were used for structure solution, structure refinement, and ORTEP plot, respectively.15−17  
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Crystallographic data for the structures for compounds 1−5 have been deposited with the 
Cambridge Crystallographic Data Centre (Deposition numbers: CCDC 1046089−1046093). 
Copies of these data can be obtained, free of charge, on application to the Director, CCDC, 
12 Union Road, Cambridge CB2 1EZ, UK (fax: +44-(0)1223-336033 or e-mail: 
deposit@ccdc.cam.ac.uk).  
Crystal Data of Kaempulchraol A (1): C21H34O2, M = 318.49, orthorhombic, space group 
P212121, a = 6.108 (2) Å, b = 11.902 (3) Å, c = 24.407 (9) Å, V = 1774.2 (11) Å3, Z = 4, Dcalcd 
= 1.140 g/cm3, T = 100 K, F(000) = 672, and µ (Mo Kα) = 0.071 mm−1. A total of 10461 
reflections (4495 unique, Rint = 0.0557) were collected from 1.66° to 29.45° in θ and index 
ranges 8 ≥ h ≥ −8, 8 ≥ k ≥ −16, 30 ≥ l ≥ −33. The final stage converged to R1 = 0.0640 (wR2 = 
0.1546) for 4264 observed reflections [with I > 2σ(I)] and 214 variable parameters and R1 = 
0.0669 (wR2 = 0.1564) for all unique reflections and GoF = 1.111. 
Crystal Data of Kaempulchraol B (2): C21H34O2, M = 318.49, monoclinic, space group P21, 
a = 7.4283 (4) Å, b = 21.5310 (11) Å, c = 12.2627 (6) Å, β = 104.9149° (6), V = 1895.20 (17) 
Å3, Z = 4, Dcalcd = 1.067 g/cm3, T = 100 K, F(000) = 672, and µ (Mo Kα) = 0.066 mm−1. A 
total of 11747 reflections (8692 unique, Rint = 0.0137) were collected from 1.71° to 29.23° in 
θ and index ranges 10 ≥ h ≥ −9, 27 ≥ k ≥ −29, 16 ≥ l ≥ −7. The final stage converged to R1 = 
0.0295 (wR2 = 0.0762) for 8555 observed reflections [with I > 2σ(I)] and 427 variable 
parameters and R1 = 0.0300 (wR2 = 0.0767) for all unique reflections and GoF = 1.011. 
Crystal Data of Kaempulchraol C (3): C20H32O2, M = 304.46, monoclinic, space group 
P21, a = 11.3576 (8) Å, b = 12.9484 (9) Å, c = 24.0498 (17) Å, β = 89.9595° (9), V = 3536.8 
(4) Å3, Z = 8, Dcalcd = 1.144 g/cm3, T = 100 K, F(000) = 1344, and µ (Mo Kα) = 0.071 mm−1. 
A total of 22053 reflections (16184 unique, Rint = 0.0221) were collected from 0.84° to 
29.28° in θ and index ranges 15 ≥ h ≥ −15, 16 ≥ k ≥ −17, 32 ≥ l ≥ −20. The final stage 
converged to R1 = 0.0368 (wR2 = 0.0853) for 15714 observed reflections [with I > 2σ(I)] and 
817 variable parameters and R1 = 0.0379 (wR2 = 0.0856) for all unique reflections and GoF = 
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2.926. 
Crystal Data of Kaempulchraol D (4): C20H32O2, M = 304.46, orthorhombic, space group 
P21212, a = 20.378 (2) Å, b = 22.837 (3) Å, c = 11.6754 (13) Å, V = 5433.4 (11) Å3, Z = 12, 
Dcalcd = 1.117 g/cm3, T = 100 K, F(000) = 2016, and µ (Mo Kα) = 0.070 mm−1. A total of 
29692 reflections (11243 unique, Rint = 0.0446) were collected from 1.33° to 26.52° in θ and 
index ranges 25 ≥ h ≥ −25, 28 ≥ k ≥ −28, 14 ≥ l ≥ −8. The final stage converged to R1 = 
0.0579 (wR2 = 0.1457) for 9809 observed reflections [with I > 2σ(I)] and 613 variable 
parameters and R1 = 0.0667 (wR2 = 0.1516) for all unique reflections and GoF = 0.945. 
Crystal Data of Kaempulchraol E (5): C20H32O2, M = 304.46, monoclinic, space group P21, 
a = 7.5976 (5) Å, b = 11.1628 (7) Å, c = 42.287 (3) Å, α = 90°, β = 90°, γ = 90°, V = 3586.4 
(4) Å3, Z = 8, Dcalcd = 1.128 g/cm3, T = 100 K, F(000) = 1344, and µ (Mo Kα) = 0.070 mm−1. 
A total of 22137 reflections (15455 unique, Rint = 0.0371) were collected from 0.96° to 
29.21° in θ and index ranges 10 ≥ h ≥ −10, 14 ≥ k ≥ −14, 39 ≥ l ≥ −57. The final stage 
converged to R1 = 0.0650 (wR2 = 0.1681) for 14617 observed reflections [with I > 2σ(I)] and 
817 variable parameters and R1 = 0.0679 (wR2 = 0.1707) for all unique reflections and GoF = 
0.987. 
In Vitro Antiproliferative Activity. The cell lines used were A549 (human lung cancer), 
HeLa (human cervix cancer), TIG-3 (normal human primary fibroblast cell), PANC-1 and 
PSN-1 (human pancreatic cancer), and MDA-MB-231 (human breast cancer). The 
α-minimum essential medium with L-glutamine and phenol red (α-MEM, Wako) was used 
for the first three cell lines whereas the high glucose Dulbecco’s modified Eagle’s medium 
with L-glutamine, phenol red, and sodium pyruvate (DMEM, Wako) were used for the latter 
ones. Both media were supplemented with 10% fetal bovine serum (FBS, Nichirei 
Bioscience) and 1% antibiotic antimycotic solution (Sigma-Aldrich).  
The in vitro antiproliferative activity of crude extracts  and isolated compounds was 
determined by the procedure as described previously.18 Briefly, each cell line was seeded in 
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96-well plates (2 × 103 per well) and incubated either in α-MEM or DMEM at 37 °C under 
5% CO2 and 95% air for 24 h. After the cells were washed with PBS (Nissui 
Pharmaceuticals), serial dilutions of the tested samples were added. After 72 h incubation, the 
cells were washed with PBS, and 100 µL of α-MEM or DMEM containing 10% WST-8 cell 
counting kit (Dojindo; Kumamoto, Japan) solution was added to the wells. After 2 h 
incubation, the absorbance at 450 nm was measured. The different concentrations of serial 
dilution of tested samples were 100−3.125 µg/mL for crude extract, 100−3.125 µM for 
isolated compounds, and 10−0.3125 µM for positive control, respectively. Cell viability was 
calculated from the mean values of data from three wells by using the following equation and 
antiproliferative activity was expressed as IC50 (50% inhibitory concentration) value. 
5-Fluorouracil was used as positive control. The IC50 values for the antiproliferative activity 
of 5-fluorouracil against A549, HeLa, PANC-1, PSN-1, MDA-MB-231, and TIG-3 were 2.8, 
5.8, 3.7, 4.4, 5.2, and 8.4 µM respectively.  
 (%) Cell viability = 100 × [{Abs(test samples) − Abs(blank)}/{Abs(control) − Abs(blank)}]  
 
ASSOCIATED CONTENT 
Supporting Information 
The structures of reported compounds 9−13 (Figure S1), the COSY and key HMBC (1H → 
13C) correlations of compounds 1−8 (Figure S2), 1H and 13C NMR, 1H1−H COSY, HMQC, 
HMBC, and NOESY spectra of compounds 1−8 (Figure S3−Figure S50). CIF files and X-ray 
crystallographic data of kaempulchraols A−E (1−5). This material is available free of charge 
via the internet at http://pubs.acs.org.  
  
AUTHOR INFORMATION 
Corresponding Author 
*Tel: +81 76 434 7625. Fax: +81 76 434 5059. E-mail: hmorita@inm.u-toyama.ac.jp (H. 
15 
 
Morita). 
Notes 
The authors declare no competing financial interest. 
 
ACKNOWLEDGEMENTS 
This work was supported in part by a Grant-in Aid for Scientific Research from the Ministry 
of Education, Culture, Sports, Science and Technology, Japan (H.M. and I.A.) and by a grant 
from Tokyo Biochemical Research Foundation (H.M. and N.N.W.). We also thank to 
Masami Tanaka and Yasuko Okamoto (Tokushima Bunri University, Tokushima, Japan) for 
their technical assistance with NMR, MS and X-ray diffraction measurements. 
16 
 
REFERENCES 
(1) Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, 
M.; Parkin, D.M.; Forman, D.; Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence 
and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: 
International Agency for Research on Cancer; 2013. Available from: 
http://globocan.iarc.fr, accessed on 24/January/2015. 
(2) Rocha, A. B.; Lopes, R. M.; Schwartsmann, G. Curr. Opin. Pharmacol. 2001, 1, 
364−369. 
(3) Win, N. N.; Awale, S.; Esumi, H.; Tezuka, Y.; Kadota, S. J. Nat. Prod. 2007, 70, 
1582−1587. 
(4) Win, N. N.; Awale, S.; Esumi, H.; Tezuka, Y.; Kadota, S. Chem. Pharm. Bull. 2008, 
56, 491−496. 
(5) Win, N. N.; Awale, S.; Esumi, H.; Tezuka, Y.; Kadota, S. Bioorg. Med. Chem. Lett. 
2008, 18, 4688−4691. 
(6) Win, N. N.; Awale, S.; Esumi, H.; Tezuka, Y.; Kadota, S. Bioorg. Med. Chem. 2008, 
16, 8653−8660. 
(7) The Traditional Medicine Formulations used in Myanmar Traditional Medicine; 
Department of Traditional Medicine, Ministry of Health, Myanmar, 1990. 
(8) Tuchinda, P.; Udchachon, J.; Reutrakul, V.; Santisuk, T.; Skelton, B. W.; White, A. 
H.; Taylor, W. C. Phytochemistry 1994, 36, 731−734. 
(9) Prasad, S.; Yadav, V. R.; Sundaram, C.; Reuter, S.; Hema, P. S.; Nair, M. S.; 
Chaturvedi, M. M.; Aggarwal, B. B. J. Biol. Chem. 2010, 285, 26987−26997. 
(10) Prawat,  U.; Tuntiwachwuttikul, P.; Taylor, W. C.; Engelhardt, L. M.; Skelton, B. 
W.; White, A. H. Phytochemistry 1993, 32, 991−997.  
(11) Chang, C. I.; Tseng, M. H.; Kuo, Y. H. Chem. Pharm. Bull. 2005, 53, 286−289. 
(12) Xia, X.; Zhang, J.; Zhang, Y.; Wei, F.; Liu, X.; Jia, A.; Liu, C.; Li, W.; She, Z.; Lin, 
17 
 
Y. Bioorg. Med. Chem. Lett. 2012, 22, 3017−3019. 
(13) Thongnest, S.; Mahidol, C.; Sutthivaiyakit, S.; Ruchirawat, S. J. Nat. Prod. 2005, 68, 
1632−1636. 
(14) Nagashima, F.; Murakami, M.; Takaoka, S.; Asakawa, Y. Phytochemistry 2003, 64, 
1319−1325. 
(15) Sheldrick, G. M. Acta Cryst. 1990, A46, 467−473. 
(16) Sheldrick, G. M. SHELXL2014. University of Göttingen, Germany. 
(17) Spek, A. L. Acta Cryst. 2009, D65, 148−155. 
(18) Feng, L.; Awale, S.; Tezuka, Y.; Kadota, S. Biol. Pharm. Bull. 2009, 32, 2075−2078. 
18 
 
Table 1. 1H NMR Spectroscopic Data (600 MHz, CDCl3) of Kaempulchraols A−D (1−4), (δ  in ppm and J 
Values in (Hz) in Parentheses) 
Position 1 2 3 4 
1α 1.14, m 1.02, m 1.12, m 1.03, m 
1β 1.69, m 1.67a, m 1.71, m 1.67a, m 
2α 1.49, m 1.47, m 1.50a, m 1.48, m 
2β 1.65, m 1.67a, m 1.67, m 1.67a, m 
3α 1.16, m 1.14, m 1.17, m 1.17, m 
3β 1.39a, m 1.38a, m 1.40, m 1.39, m 
5α 1.27, br s 1.13, br s 1.23a, m 1.16, br s 
6α 4.54, t (5.0) 4.50, d (5.0) 4.54, br s 4.53, d (5.1) 
7α 2.78, m 2.30, m 2.75, m 2.31, m 
7β 1.94a, m 2.36, m 2.01a, m 2.50, m 
11α 2.13, m 1.91, m 2.17, m 1.99a, m 
11β 1.94a, m 1.99, m 2.01a, m 1.99a, m 
12α 1.69, m 1.62, m 1.74, m 1.43, m 
12β 1.39a, m 1.38a, m 1.50a, m 1.58, m 
14α  2.93, br s  3.37, br s 
14β 3.13, s  3.61, d (6.1)  
15 6.07, dd (16.5, 12.0) 5.77, dd (17.6, 11.1) 5.97, dd (17.7, 10.9) 5.74, dd (17.6, 11.1) 
16-a 5.07, dd (16.5, 1.5) 4.94, dd (17.6, 1.3) 5.15, dd (17.7, 1.5) 4.96, dd (17.6, 1.4) 
16-b 5.05, dd (12.0, 1.5) 4.96, dd (11.1, 1.3) 5.20, dd (10.9, 1.5) 4.97, dd (11.1, 1.4) 
17 1.03, s 1.10, s 1.05, s 1.07, s 
18 1.23, s 1.23, s 1.23a, s 1.22, s 
19 0.98, s 0.99, s 0.98, s 0.99, s 
20 1.38, s 1.37, s 1.39, s 1.36, s 
OMe-14 3.46, s 3.50, s   
aOverlapping resonances within the same column, δ values were measured from HMQC spectrum. 
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Table 2. 1H NMR Spectroscopic Data (600 MHz, CDCl3) of Kaempulchraols E−H (5−8), (δ  in ppm and J 
Values in (Hz) in Parentheses) 
Position 5 6 7 8 
1α   1.10, m  
1β 3.64, br s 3.75, br s 1.74a, m 3.64, br s 
2α 1.56, dq (14.4, 3.6) 2.05a, q (2.9) 1.53, m 2.01, dt (15.1, 2.7) 
2β 1.92, tq (14.4, 2.2) 2.05a, q (2.9) 1.74a, m 2.10, dt (15.1, 3.3) 
3α 1.70, td (13.8, 3.5)  1.16, m  
3β 1.14, dt (13.4, 3.4) 3.57, br s 1.42, m 3.52, br s 
5α 1.47, d (1.7) 1.77, dd (12.5, 2.7) 1.12, br s 1.78, d (1.7) 
6α 4.36, d (2.3) 1.60, m 4.60, d (4.05) 4.33, d (2.5) 
6β  1.43, m   
7α 2.33a, m 2.10, m  2.41, m 2.40, dq (14.4, 1.9) 
7β 2.23a, m 2.28, m 2.54, m 2.26, dd (14.4, 2.7) 
9 α 2.37, br d (7.1) 2.41, t (7.2)  2.52, t (7.0) 
11α 1.66, m 1.67, m 2.32a, m 1.66, m 
11β 1.60, m 1.50, m 2.32a, m 1.57, m 
12α 1.42, m 1.42−1.48a, m 1.95, m 1.42, m 
12β 1.49, m 1.42−1.48a, m 1.84, m 1.49, m 
14 5.43, br t (1.7) 5.28, br s  5.44, br s 
15 5.77, dd (17.7, 10.3) 5.79, dd (17.4, 10.5) 5.80, dd (17.5, 10.7) 5.77, dd (17.7, 10.3) 
16-a 4.92, dd (17.7, 1.5) 4.92, dd (17.4, 1.4) 4.90, dd (17.5, 0.8) 4.93, dd (17.7, 1.4) 
16-b 4.90, dd (10.3, 1.5) 4.89, dd (10.5, 1.4) 5.03, dd (10.7, 0.8) 4.91, dd (10.3, 1.4) 
17 1.09a, s 1.05, s 1.18, s 1.09, s 
18 1.26, s 0.89, s 1.24, s 1.27, s 
19 1.03, s 1.03, s 1.00, s 1.12, s 
20 1.09a, s 0.79, s 1.47, s 1.08, s 
aOverlapping resonances within the same column, δ values were measured from HMQC spectrum. 
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Table 3. 13C NMR Spectroscopic Data (150 MHz, CDCl3) of Kaempulchraols A−H (1−8), (δ  in ppm) 
 
δ Values were measured from HMQC spectrum. 
Position 1 2 3 4 5 6 7 8 
1 40.18 39.7 40.1 39.7 73.4 73.8 38.9 75.3 
2 19.4 19.2 19.3 19.4 26.1 30.0 19.1 29.9 
3 43.3 43.2 43.3 43.3 36.0 78.1 42.9 79.4 
4 34.3 34.2 34.2 34.3 34.1 38.0 34.3 38.8 
5 53.6 53.9 53.7 53.9 50.1 42.6 53.1 44.4 
6 66.1 65.9 65.8 65.9 68.9 22.4 64.9 69.1 
7 40.7 40.7 40.5 40.6 45.8 35.8 35.8 45.9 
8 123.7 122.7 123.9 123.9 134.0 137.6 126.0 133.9 
9 140.7 141.5 140.8 141.8 42.7 43.5 164.4 42.6 
10 37.8 37.4 37.7 37.7 40.0 42.5 39.1 43.5 
11 20.4 21.2 20.4 21.3 18.0 18.3 22.1 17.9 
12 31.4 30.4 30.6 29.4 34.3 34.6 35.5 34.3 
13 40.17 40.5 40.3 39.8 37.9 37.6 47.7 37.9 
14 88.9 85.2 77.5 74.8 133.0 129.3 202.1 133.1 
15 144.4 144.5 142.9 144.1 148.4 149.2 140.9 148.4 
16 112.4 112.2 115.5 112.8 110.9 110.3 114.5 110.9 
17 22.9 23.3 23.0 23.6 26.8 26.2 24.5 26.8 
18 24.3 23.8 24.1 24.1 24.4 22.7 24.1 24.2 
19 33.7 33.6 33.7 33.8 33.9 28.7 33.6 28.8 
20 21.9 21.4 21.6 21.4 19.0 15.3 20.7 18.6 
OMe-14 62.1 61.8       
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Chart 1. Structures of kaempulchraols A−H (1−8). 
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Figure 1. X-ray crystallographic structures of kaempulchraols A−E (1−5). 
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